Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: Interleukin-6 response is a potential early indicator of response to therapy

Journal of Interferon and Cytokine Research

Volumn 29, Issue 2, 2009, Pages 105-111

  Woods Ignatoski, Kathleen M ^a   Friedman, Judah ^a   Escara Wilke, June ^a   Zhang, Xiaohua ^a   Daignault, Stephanie ^b   Dunn, Rodney L ^a   Smith, David C ^a,c   Keller, Evan T ^a,c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; DOCETAXEL; ESTRAMUSTINE; INTERLEUKIN 6; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METABOLISM; BONE REMODELING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; BLOOD; BONE; CONTROLLED STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; ESTRAMUSTINE; HUMANS; IMIDAZOLES; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 59349118505     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0024     Document Type: Article

References (35)

1. Akimoto S, Okumura A, Fuse H. 1998. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J 45(2):183-189.
2. Berenson J. 2005. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10:52-62.
3. Brown J, Corey E, Lee Z, True LD, Yun TJ, Tondravi M, Vessela RL. 2001. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611-616.
4. Brubaker KD, Brown LG, Vessella RL, Corey E. 2006. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6:15.
5. Bubley G, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg W, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small E, Smith M, Trump D, Wilding G. 1999. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 17(11):3461-3467.
6. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani S. 2006. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107:289-298.
7. Coleman R, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, Rubens RD. 1988. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol 24:1211-1217.
8. Coleman R, Purohit O, Black C. 1999. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 10:311-316.
9. Cook R, Coleman R, Brown J, Lipton A, Major P, Hei Y, Saad F, Smith M. 2006. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12(11Pt1):3361-3367.
10. Dattoli M, Wallner K, True L, Cash J, Sorace R. 2007. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110(3):551-555.
11. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L, Rolfe M, Ross J, Gascon P, Albanell J, Mellado B. 2006. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12(18):5578-5586.
12. Ershler W, Keller E. 2000. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51(245-270).
13. Francini G, Bigazzi S, Leone V, Gennari C. 1988. Serum osteocalcin concentration in patients with prostatic cancer. Am J Clin Oncol 11(Suppl 2):S83-S87.
14. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. 2000a. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82:858-864.
15. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman R, Delmas P. 2000b. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82(4):858-864.
16. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price P, Christensen I. 2007. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. J. Clin Cancer Res 13:3244-3249.
17. Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, Loening S, Schnorr D. 2004. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111(5):783-791.
18. Karin M, Yamamoto Y, Wang Q. 2004. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26.
19. Keller ET. 2002. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 38(2):91-102.
20. Kirstein B, Chambers T, Fuller K. 2006. Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem 98:1085-1094.
21. Le Page C, Koumakpayi I, Lessard L, Mes-Masson AM, Saad F. 2005. EGFR and HER-2 regulate the constitutive activation of KF-KappaB in PC-3 prostate cancer cells. The Prostate 65:130-140.
22. Lein M, Wirth M, Miller K, Eickenberg H, Weißbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening S, Jung K. 2007. Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression. Eur Urol Epub ahead of print.
23. Marcellini M, De Carli P, Abbolito MR, Mainiero G, Cantiani R. 1992. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer. Eur Urol 21(Suppl 1):102-104.
24. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Köhn H, Bayer P, Thiébaud D. 1997. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90:3743-3750.
25. Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos N, Economopoulos T, Raptis S. 2005. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 25(2B):1457-1463.
26. Ray A, LaForge K, Sehgal P. 1990. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10(11):5736-5746.
27. Ross J, Kallakury B, Sheehan C. 2004. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10:2466-2472.
28. Rummukainen J, Salminen T, Lundin J, Joensuu H, Isola JJ. 2001. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod. Pathol 14:1030-1035.
29. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M; Zoledronic Acid Prostate Cancer Study Group. 2004a. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNCI 96:879-882.
30. Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin J, Vinholes J, Goas J, Zheng M, Group ZAPCS. 2004b. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNCI 96(11):879-882.
31. Scher H, Warren M, Heller G. 2007. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 13:1488-1492.
32. Smith P, Hobisch A, Lin D, Culig Z, Keller ET. 2001. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12:33-40.
33. Soloway M, Hardeman S, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. 1988. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195-202.
34. Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. 2001. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19(1):45-51.
35. Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Rédini F. 2004. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704:49-57.